US EditionUnlocking a New Target Against Crimean-Congo Hemorrhagic Fever Virus
Summary by Global Biodefense
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Unlocking a New Target Against Crimean-Congo Hemorrhagic Fever Virus
New research identifies Cepharanthine, an FDA-approved drug, as a potent antiviral against Crimean-Congo hemorrhagic fever virus (CCHFV), a tick-borne pathogen and U.S. Federal Select Agent. The study highlights a novel therapeutic strategy targeting viral RNA structures to combat this high-consequence threat to global health security.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium